|Contents of Shopping Cart|
Khedezla is indicated for the treatment of which of the following?
d. Type II diabetes
Answer: (b) Depression
The active ingredient found in Khedezla is Desvenlafaxine. Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of the antidepressant Effexor (Venlafaxine), a medication used to treat major depressive disorder.
Khedezla contains the serotonin and norepinephrine reuptake inhibitor (SNRI) Desvenlafaxine, which is also contained in Pristiq. Pristiq was approved by the FDA in 2008 and contains Desvenlafaxine as the succinate salt.
Khedezla will be available in 50 mg and 100 mg strengths for once daily administration. The recommended dose for Khedezla is 50 mg once daily, with or without food. It should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.
In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses.
Nausea, dizziness, insomnia, hyperhidrosis (excessive sweating), constipation, drowsiness, decreased appetite, anxiety, and specific male sexual function disorders are commonly reported side effects of the drug.